Related Experiment Videos

Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines

S Hougaard1, P Nørgaard, N Abrahamsen

  • 1Section for Radiation Biology, The Finsen Center, University Hospital of Copenhagen, Denmark.

Insights

Transforming growth factor beta receptor II (RII) is often absent in small cell lung cancer (SCLC). This study found RII absence is rarely due to mutations or promoter hypermethylation in SCLC cell lines.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cancer Research

Background:

  • Transforming growth factor beta (TGF-beta) inhibits cell growth via type I and II receptors.
  • Lack of TGF-beta receptor II (RII) expression is observed in some cancers, including small cell lung cancer (SCLC).

Purpose of the Study:

  • To investigate the molecular mechanisms underlying the absent RII expression in SCLC cell lines.

Main Methods:

  • Northern blot analysis to assess RII RNA expression.
  • Screening for mutations in the RII gene and its poly-A tract.
  • Southern blot analysis to evaluate RII promoter methylation.
  • Treatment with 5-aza-2'-deoxycytidine to assess RII expression induction.

Main Results:

  • RII RNA expression was very weak in 16 of 21 SCLC cell lines.
  • No mutations were detected in the RII poly-A tract; one cell line had a GG to TT substitution causing a premature stop codon.
  • RII promoter methylation patterns were not altered, and RII gene expression was not induced by demethylation treatment.

Conclusions:

  • Absent RII mRNA expression in SCLC is not commonly caused by mutations or promoter hypermethylation.
  • In most SCLC cell lines, the RII gene and promoter appear intact despite absent RII expression.
  • A specific RII mutation identified may be linked to benzo[a]-pyrene exposure from cigarette smoke.

Related Concept Videos